Value of serum matrix metalloproteinase 3 in the assessment of early rheumatoid arthritis / 北京大学学报(医学版)

OBJECTIVE@#To investigate the expression level of serum matrix metalloproteinase 3 (MMP3) in early rheumatoid arthritis (ERA) patients with normal C-reaction protein (CRP) or erythrocyte sedimentation rate (ESR), and the significance in disease assessment.@*METHODS@#In the study, 133 cases of early RA patients, 25 osteoarthritis (OA) patients and 60 healthy controls in Peking University People's Hospital from 2011 to 2015 were included. The RA patients were further divided into 4 groups according to levels of CRP and ESR: 88 patients with increased CRP and increased ESR, 15 patients with normal CRP and normal ESR, 17 patients with normal CRP but increased ESR, and 13 patients with increased CRP but normal ESR. All the clinical information of the patients was collected, and the serum MMP3 levels of both patients and healthy controls were detected by enzyme-linked immune sorbent assay (ELISA).@*RESULTS@#The serum MMP3 level of RA patients with normal CRP and/or normal ESR [(72.89±6.34) μg/L] was obviously higher than that of OA patients [(42.87±4.14) μg/L] (P=0.002) and healthy controls [(31.62±2.88) μg/L] (P<0.001). The serum MMP3 levels of the patients with normal CRP and normal ESR [(47.04±9.64) μg/L] were higher than those of the healthy controls, and there was statistical significance between the two groups (P<0.05). The serum MMP3 levels of the patients with increased CRP but normal ESR [(94.18±9.11) μg/L] and the patients with normal CRP but increased ESR [(79.42±10.60) μg/L] were both higher than those of the OA patients and healthy controls, and there was obvious statistical difference (P<0.05). In the early RA patients with normal CRP and/or normal ESR, the serum MMP3 level was positively correlated with the CRP level (r=0.336, P=0.024). The positive rate of MMP3 in the patients with normal CRP and/or normal ESR was 44.44%, higher than the positive rate of CRP (28.89%) and the positive rate of ESR (37.78%). In these early RA patients, the positive rate was 52.94% in the patients with normal CRP but increased ESR and 53.85% in the patients with increased CRP but normal ESR.@*CONCLUSION@#The detection of the serum MMP3 level was significant in the assessment of early RA patients within 2-year duration who had normal CRP or ESR value.

Inhalation Therapy of Calcitonin Relieves Osteoarthritis of the Knee

This study was conducted to determine if nasal salmon calcitonin has additional beneficial effects on clinical symptoms, serum NO, IL-1beta, matrix metalloproteinase 3, urinary C-terminal telopeptide type II collagen (CTX-II) levels and MRI findings in knee osteoarthritis (OA) when used concomitantly with exercise therapy. Fifty female patients with knee OA were randomized into two groups. The first group (n = 30) received 200 IU/day nasal salmon calcitonin and a home exercise program; the second group (n = 20) received a home exercise program for 6 months. Compared with baseline,while significant improvements were observed in visual analogue scale (VAS), WOMAC pain, physical function scores, 20-m walking time (P < 0.001) and WOMAC stiffness score (P = 0.041) in the first group, walking and resting VAS, and WOMAC physical function scores were improved (P = 0.029) in the second group after treatment. Significantly increased levels of serum NO and urinary CTX-II (P < 0.001) and significant improvements in the area of medial femoral condyle (P < 0.05) were noted only in the first group. There were significant differences in VAS activation values (P = 0.032) and NO levels (P < 0.001) in the favor of the first group. In conclusion, nasal salmon calcitonin may have possible chondroprotective effects besides its known effects on symptoms in patients with knee OA.

Inhalation Therapy of Calcitonin Relieves Osteoarthritis of the Knee

This study was conducted to determine if nasal salmon calcitonin has additional beneficial effects on clinical symptoms, serum NO, IL-1beta, matrix metalloproteinase 3, urinary C-terminal telopeptide type II collagen (CTX-II) levels and MRI findings in knee osteoarthritis (OA) when used concomitantly with exercise therapy. Fifty female patients with knee OA were randomized into two groups. The first group (n = 30) received 200 IU/day nasal salmon calcitonin and a home exercise program; the second group (n = 20) received a home exercise program for 6 months. Compared with baseline,while significant improvements were observed in visual analogue scale (VAS), WOMAC pain, physical function scores, 20-m walking time (P < 0.001) and WOMAC stiffness score (P = 0.041) in the first group, walking and resting VAS, and WOMAC physical function scores were improved (P = 0.029) in the second group after treatment. Significantly increased levels of serum NO and urinary CTX-II (P < 0.001) and significant improvements in the area of medial femoral condyle (P < 0.05) were noted only in the first group. There were significant differences in VAS activation values (P = 0.032) and NO levels (P < 0.001) in the favor of the first group. In conclusion, nasal salmon calcitonin may have possible chondroprotective effects besides its known effects on symptoms in patients with knee OA.

Serum matrix metalloproteinase-3 as a disease activity marker in patients with rheumatoid arthritis

To analyze the clinical significance of measurement of serum matrix metalloproteinase-3 [MMP-3] levels in relation to systemic markers of inflammation, functional status, disease activity parameters and degree of joint damage assessed radiologically in patients with rheumatoid arthritis [RA]. Forty adult patients with RA and 10 healthy controls had serum samples tested with indirect sandwich enzyme-linked immunosorbent assay for MMP-3. Patients were assessed clinically for Ritchie articular index score [RAI], Steinbrocker score, Health Assessment Questionnaire [HAQ], Disease activity score including a 28-joint count [DAS 28] and Chronic arthritis systemic index [CASI]. Then, plain radiograph of both hands and feet were obtained and the mdified Larsen score was used to assess joint damage. Recent C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR] were recorded. MMP-3 level in RA patients was significantly higher than that in the control group [p=0.043]. Serum levels of MMP-3 show significant correlation with disease duration, CRP, ESR, Steinbrocker score, DAS 28 and modified Larsen score [in the two subgroups of patients: erosive and non-erosive]. No correlation was found between MMP-3 levels and patients' age, RAI, HAQ or CASI. MMP-3 is a single variable that correlates with disease activity and seems to be useful for early diagnosis and follow-up of patients with RA

Correlation between progressive joint damage and serum level of matrix metalloproteinases: MMP-3 and MMP-1 in early rheumatoid arthritis[RA]

There are a group of rheumatoid arthritis [RA] patients for whom traditional markers of outcome are unhelpful. Despite of absence of these markers; still they have progressive damaging arthritis. Expression and activation of matrix metalloproteinases as MMP-3 [stromolysin-1] and MMP-1 [collagenase-1] are increased in RA patients. There are contradictory results of their role as predictors of joint damage. To study the role of MMP-3 and MMP-1 as predictors of joint damage in early RA. Seventy early RA patients of less than 12 months duration fulfilling the ACR criteria for classification of RA were enrolled in this study. They were 65 females and 5 males with mean age [30.5 +/- 3.2] years. Also 30 apparently healthy persons were studied as a control group, 15 males and 15 females with mean age of [33.5 +/- 2.8] years. All patients and control volunteers were tested for MMP-3 and MMP-1 basal serum level, using an Enzyme-Linked Immunosorbent Assay [ELISA]. The subsequent change of Larsen Radiological Score [delta Larsen] and Health Assessment Questionnaire [delta HAQ] were recorded and correlated with MMP-3 and MMP-1 over a 12 months period. The mean basal serum level of MMP-3 and MMP-1 were significantly higher in RA patients than controls [p<0.05]. MMP-3 and MMP-1 serum levels at presentation of RA patients correlated significantly with basal CRP presentation [r = 0.40, r=0.47 and p<0.05], with delta Larsen Score [r = 0.24, r = 0.31 and p<0.05], and with delta HAQ [r = 0.33, r = 0.31 and p<0.05]. The group of patients with normal CRP at presentation [

Oncostatin-M and matrix metalloproteinase-3 production in rheumatoid arthritis and osteoarthritis

To evaluate the significance of measuring serum levels of Oncostatin-M [OS-M] and matrix metalloproteinase-3 [MMP-3] in the assessment of rheumatoid arthritis [RA] and osteoarthritis [OA]. The study was performed on 15 RA, 15 OA patients and 10 controls age and sex matched. Laboratory and clinical data for all the patients were assessed and serum MMP-3 and OS-M were measured in all subjects. Statistical analysis and correlations were done for all the data. Serum levels of MMP-3 and OS-M were higher in RA than OA patients and controls. The difference was of a high statistical significance [p<0.001, p<0.001]. In RA patients OS-M level correlated positively with MMP-3 level [r=0.826] but OS-M and MMP-3 did not correlate with any parameters of disease activity. There was a significant difference in serum levels of OS-M and MMP-3 in patients taking steroid therapy and those who were not on steroid therapy. In OA patients, serum MMP-3 and OS-M were also higher than those of controls and the difference was highly significant. MMP-3 in OA patients correlated positively with ESR [r=0.77] and this was higher in patients with severe erosive changes. Measuring serum MMP-3 and OS-M is necessary for evaluating synovial inflammation and cartilage destruction in RA and OA patients. Using MMP inhibitor may be useful to stop the progression of synovitis and erosions